GlaxoSmithKline ROE 2006-2018 | GSK

Current and historical return on equity (ROE) values for GlaxoSmithKline (GSK) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. GlaxoSmithKline ROE for the three months ending September 30, 2018 was 164.99%.
GlaxoSmithKline ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2018-09-30 $2.83B $4.85B 61.39%
2018-06-30 $2.57B $4.11B 51.62%
2018-03-31 $1.74B $5.00B 32.45%
2017-12-31 $1.98B $4.50B 33.75%
2017-09-30 $3.05B $6.32B 47.56%
2017-06-30 $2.52B $5.66B 41.07%
2017-03-31 $2.13B $6.93B 34.09%
2016-12-31 $1.24B $6.73B 18.04%
2016-09-30 $0.30B $5.25B 3.50%
2016-06-30 $0.07B $6.06B 0.67%
2016-03-31 $0.93B $9.37B 6.91%
2015-12-31 $12.77B $13.57B 83.05%
2015-09-30 $14.87B $14.47B 106.07%
2015-06-30 $14.68B $16.16B 114.69%
2015-03-31 $15.57B $17.30B 133.77%
2014-12-31 $4.44B $8.14B 42.76%
2014-09-30 $6.81B $9.61B 59.68%
2014-06-30 $7.73B $11.51B 66.37%
2014-03-31 $8.22B $12.30B 71.10%
2013-12-31 $8.56B $12.22B 74.82%
2013-09-30 $6.01B $10.54B 54.31%
2013-06-30 $6.25B $11.17B 55.78%
2013-03-31 $6.62B $11.84B 57.63%
2012-12-31 $7.30B $10.70B 59.34%
2012-09-30 $7.90B $11.10B 60.00%
2012-06-30 $8.28B $12.35B 60.44%
2012-03-31 $8.10B $15.04B 56.01%
2011-12-31 $8.41B $14.16B 57.33%
2011-09-30 $5.32B $13.27B 35.72%
2011-06-30 $5.21B $15.40B 33.21%
2011-03-31 $2.98B $15.83B 19.36%
2010-12-31 $2.60B $15.07B 16.32%
2010-09-30 $6.44B $16.45B 40.10%
2010-06-30 $6.60B $14.24B 41.94%
2010-03-31 $9.29B $17.84B 61.25%
2009-12-31 $8.92B $15.67B 65.52%
2009-09-30 $7.69B $15.23B 56.74%
2009-06-30 $7.93B $11.95B 59.69%
2009-03-31 $8.27B $11.59B 59.20%
2008-12-31 $9.23B $15.43B 58.93%
2008-09-30 $9.93B $14.20B 59.78%
2008-06-30 $10.15B $14.67B 56.25%
2008-03-31 $10.24B $18.33B 51.88%
2007-12-31 $10.60B $19.22B 57.58%
2007-09-30 $10.71B $19.97B 59.76%
2007-06-30 $10.69B $21.43B 62.01%
2007-03-31 $10.46B $13.02B 65.76%
2006-12-31 $10.15B $17.30B 61.45%
2006-09-30 $9.86B $17.18B 63.52%
2006-06-30 $9.40B $16.11B 65.47%
2006-03-31 $9.10B $15.46B 68.59%
2005-12-31 $8.74B $13.31B 72.67%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $101.752B $38.892B
GlaxoSmithKline is one of the world's leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $390.684B 18.32
Pfizer (PFE) United States $262.581B 14.80
Novartis AG (NVS) Switzerland $204.469B 17.47
Merck (MRK) United States $201.378B 17.45
AbbVie (ABBV) United States $134.913B 11.98
Eli Lilly (LLY) United States $119.915B 21.08
Sanofi (SNY) France $111.886B 13.85
Novo Nordisk (NVO) Denmark $108.835B 17.67
AstraZeneca (AZN) United Kingdom $103.621B 12.86
Bristol-Myers Squibb (BMY) United States $86.262B 14.21